Literature DB >> 10231704

[Endonasal, microsurgical approach to the retrobulbar region exemplified by intraconal hemangioma].

P A Mir-Salim1, A Berghaus.   

Abstract

The posterior orbit contain's a number of important and vulnerable structures, including the optic nerve, the opthalmic artery and vein, the ocular muscles and their motor nerves. Because of their close relation to the ocular bult, surgical access to this region is very difficult. Transfrontal, transfrontal-ethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures. The endonasal microsurgical transethmoid access is described here along with a case report of a 2 x 1 cm intraconal hemangioma. Ethmoidectomy was performed after septal mobilization. The optic nerve was identified in the wall of the sphenoid sinus. The lamina papyracea was resected between the sphenoid sinus wall, skull base and ethmoid. The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor. The hemangioma was then removed in toto under microscopic control. Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique. The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions.

Entities:  

Mesh:

Year:  1999        PMID: 10231704     DOI: 10.1007/s001060050381

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  2 in total

Review 1.  Endoscopic treatment of orbital tumors.

Authors:  Francesco Signorelli; Carmelo Anile; Mario Rigante; Gaetano Paludetti; Angelo Pompucci; Annunziato Mangiola
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

2.  Navigational Transmaxillary Endoscopic Approach for Inferomedial Tumors.

Authors:  Cheng-Hsien Wu; Yi-Yun Ho; Tzu-Lun Liu; Tzu-Ying Wu; Han-Chieh Cheng; Chieh-Chih Tsai
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.